Fernando Martinez

Fernando Martinez is a Professor and holds the Joseph D. Early Chair in Biomedical Research at UMass Chan Medical School, where he is affiliated with the Department of Medicine in the T.H. Chan School of Medicine. His research focuses on pulmonary medicine, particularly chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and interstitial lung diseases (ILD).

• BS in Interdisciplinary Sciences, University of Florida
• MS in Biostatistics & Clinical Study, University of Michigan
• MD, University of Florida College of Medicine

Dr. Martinez's research interests center on understanding the pathogenesis, progression, and treatment of chronic lung diseases. He employs advanced methodologies such as quantitative CT imaging, genomics, proteomics, and machine learning to identify biomarkers and define disease endotypes. His work emphasizes precision medicine approaches to improve diagnosis, risk stratification, and therapeutic outcomes in COPD and pulmonary fibrosis.

His recent publications reveal a strong focus on clinical trials, disease phenotyping, and biomarker discovery. Key themes include the use of quantitative imaging to assess COPD severity, genetic and proteomic determinants of survival in IPF, and the development of novel therapies for progressive fibrotic lung diseases. He frequently publishes in high-impact journals and contributes to major clinical guidelines.

• Joseph D. Early Chair in Biomedical Research

Dr. Martinez is actively involved in large-scale collaborative research initiatives such as SPIROMICS and COPDGene, which investigate the heterogeneity and progression of COPD. He has led and contributed to numerous clinical trials evaluating new pharmacological treatments for COPD and IPF. His work has significant implications for clinical practice and public health policy.

He is a key contributor to multidisciplinary teams focused on interstitial lung disease and has helped shape diagnostic and management approaches through official statements from the American Thoracic Society and GOLD.